Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748170 | PMC |
| http://dx.doi.org/10.2340/actadv.v105.42291 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting the senescent surfaceome through DPP4 antibody-functionalized nanoparticles. An application to cancer therapy.
Biomaterials
January 2026
Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Universitat Politècnica de València, Universitat de València, Camino de Vera, s/n, 46022, Valencia, Spain; Unidad Mixta UPV-CIPF de Investigación en Mecanismos de Enfermedades y Nanomedicin
Due to the heterogeneity of the senescent phenotype and the lack of a universal biomarker of senescence, the targeting of senescent cells is still an unresolved challenge, and the elimination of senescent cells using specific drugs (senolytics) is still limited in clinical use due to the off-target effects and associated toxicities of current therapeutic strategies. In this study, the induction of senescence in human melanoma cells by palbociclib is found to lead to a senescent phenotype characterized by overexpression of the membrane protein dipeptidyl peptidase 4 (DPP4), previously identified only in ageing contexts. Based on this discovery, a nanoparticle targeting DPP4 overexpression in the senescent surfaceome is designed, synthesized, and characterized to target senescent cancer cells.
View Article and Find Full Text PDFPalbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real-World Data.
Clin Pharmacol Ther
April 2025
Department of Clinical Pharmacy, Tergooi Medical Centre, Hilversum, The Netherlands.
The liver is crucial for metabolizing the anticancer drug palbociclib, but limited information is available on the impact of hepatic impairment on its toxicity and efficacy, with no real-world data available. This study aims to evaluate how hepatic impairment affects hematological toxicity and progression-free survival (PFS) of palbociclib in advanced hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, using the National Cancer Institute scoring system, in a large real-world dataset. This multicenter retrospective observational study included female patients treated with palbociclib between August 2017 and February 2024.
View Article and Find Full Text PDFPalbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors.
Acta Derm Venereol
January 2025
Reims Champagne Ardenne University, Dermatology department, Reims University Hospital, IRMAIC UR7509, Reims, France.
Palbociclib-Induced Vitiligo-Like Lesions: A Report of a Challenging Case.
Cureus
June 2024
Dermatology, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Cyclin-dependent kinase (CDK) 4 and 6 inhibitors, such as palbociclib, have emerged as essential in managing hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. While effective, these inhibitors can cause rare dermatologic side effects, including vitiligo-like depigmentation. We report a rare case of a 52-year-old female with HR+, HER2- metastatic breast cancer who developed vitiligo-like depigmentation following palbociclib treatment.
View Article and Find Full Text PDFBreathless on the journey: Unmasking palbociclib-induced pneumonitis in a geriatric breast cancer warrior.
Qatar Med J
April 2024
Pulmonology Department, Hamad Medical Corporation, Doha, Qatar Email: